Targets › ATR
8 programs from 5 companies in 48 trials: 26 Phase 1, 20 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.
Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA…. (UniProt, Q13535)
Open in Phaseline: the race on ATR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | ceralasertib Serine-protein kinase ATR inhibitor | ATR | Phase 3 | Advanced or Metastatic Non-Small Cell Lung Cancer; Metastatic Triple Negative Breast Cancer; Melanoma; Non-Small Cell Lung Cancer … | Dec 2026 |
| National Cancer Institute (NCI) | Tuvusertib ATR kinase inhibitor | ATR | Phase 2 | Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Advanced Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma | Jan 2027 |
| National Cancer Institute (NCI) | Berzosertib ATR kinase inhibitor | ATR | Phase 2 | Castration-Resistant Prostate Carcinoma; Extensive Stage Lung Small Cell Carcinoma; Ovarian Serous Tumor; Bilateral Breast Carcinoma … | Feb 2027 |
| National Cancer Institute (NCI) | Elimusertib Serine-protein kinase ATR inhibitor | ATR | Phase 1 | Recurrent Alveolar Rhabdomyosarcoma; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Lung Small Cell Carcinoma; Advanced Fallopian Tube Carcinoma … | Jan 2027 |
| M.D. Anderson Cancer Center | Berzosertib (M6620) ATR (ataxia telangiectasia and Rad3-related protein) kinase inhibitor | ATR | Phase 1 | Metastatic Malignant Solid Neoplasm | Jan 2027 |
| Debiopharm International | RP-3500 ATR inhibitor | ATR | Phase 1 | Advanced Solid Tumor; Solid Tumor | Dec 2027 |
| National Cancer Institute (NCI) | Camonsertib ATR inhibitor | ATR | Phase 1 | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | May 2029 |
| Acerta Pharma | Ceralasertib (AZD6738) Serine-protein kinase ATR inhibitor | ATR | Phase 1 | Chronic Lymphocytic Leukemia | – |
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (2) Advanced Breast Carcinoma (2) Extensive Stage Lung Small Cell Carcinoma (2) Castration-Resistant Prostate Carcinoma (2) Advanced Malignant Solid Neoplasm (2) Recurrent Alveolar Rhabdomyosarcoma (1) Metastatic Lung Small Cell Carcinoma (1) Advanced Fallopian Tube Carcinoma (1) Advanced Bile Duct Carcinoma (1) Advanced Colorectal Carcinoma (1) Advanced or Metastatic Non-Small Cell Lung Cancer (1) Metastatic Triple Negative Breast Cancer (1)
small molecule (4), mixed (3), protein or peptide (1)
National Cancer Institute (NCI) (4) AstraZeneca (1) M.D. Anderson Cancer Center (1) Debiopharm International (1) Acerta Pharma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.